Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The November 2004 monograph topics are erlotinib hydrochloride, clodronate, oxypurinol sodium, pegaptanib sodium injection, and ramelteon. The DUE is on ezetimibe/simvastatin.
DahchourA., De WitteP.Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol.2000; 60(4): 343–362.
4.
WohlfarthK., SchneiderU., HaackerT.Acamprosate reduces motor cortex excitability determined by transcranial magnetic stimulation. Neuropsychobiology.2000(4);42: 183–186.
5.
StrombergM.F., MacklerS.A., VolpicelliJ.R.Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption. Alcohol.2001; 23(2): 109–116.
6.
HeyserC.J., MocK., KoobG.F.Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. Neuropsychopharmacology.2003; 28(8): 1463–1471.
7.
LittletonJ.Acamprosate in alcohol dependence: how does it work?Addiction.1995; 90(9): 1179–1188.
8.
BoeijingaP.H., ParolP., SouffletL.Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence. Neuropsychobiology.2004; 50(1): 71–77.
9.
BrasserS.M., McCaulM.E., HoutsmullerE.J.Alcohol effects during acamprosate treatment: a dose-response study in humans. Alcohol Clin Exp Res.2004; 28(7): 1074–1083.
10.
AgelinkM.W., LemmerW., MalessaR.Improved autonomic neurocardial balance in short-term abstinent alcoholics treated with acamprosate. Alcohol Alcohol.1998; 33(6): 602–605.
11.
OliveM.F., NanniniM.A., OuC.J.Effects of acute acamprosate and homotaurine on ethanol intake and ethanolstimulated mesolimbic dopamine release. Eur J Pharmacol.2002; 437(1-2): 55–61.
12.
DahchourA., De WitteP.Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods. Alcohol Clin Exp Res.2003; 27(3): 465–470.
13.
HarrisB.R., PrendergastM.A., GibsonA.Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res.2002; 26(12): 1779–1793.
14.
RammesG., MahalB., PutzkeJ.The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology.2001; 40(6): 749–760.
15.
Cano-CebrianM.J., Zornoza-SabinaT., GuerriC.Local acamprosate modulates dopamine release in the rat nucleus accumbens through NMDA receptors: an in vivo microdialysis study. Naunyn-Schmiedebergs Arch Pharmacol.2003; 367(2): 119–125.
16.
BoloN., NedelecJ-F, MuzetM.Central effects of acamprosate: part 2. Acamprosate modifies the brain in-vivo proton magnetic resonance spectrum in healthy young male volunteers. Psychiatry Res.1998; 82(2): 115–127.
17.
Cano-CebrianM.J., Zornozo-SabinaT., GuerriC.Acamprosate blocks the increase in dopamine extracellular levels in nucleus accumbens evoked by chemical stimulation of the ventral hippocampus. Naunyn-Schmiedebergs Arch Pharmacol.2003; 368(4): 324–327.
18.
SaivinS., HulotT., ChabacS.Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet.1998; 35(5): 331–345.
19.
WhitworthA.B., FischerF., LeschO.M.Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet.1996; 347(9013): 1438–1442.
20.
PailleF.M., GuelfiJ.D., PerkinsA.C.Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol.1995; 30(2): 239–247.
21.
SassH., SoykaM., MannK.Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry.1996; 53(8): 673–680.
22.
PoldrugoF.Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction.1997; 92(11): 1537–1546.
23.
GualA., LehertP.Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol.2001; 36(5): 413–418.
24.
BaltieriD.A., De AndradeA.G.Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol.2004; 65(1): 136–139.
25.
LhuintreJ.P., MooreN., TranG.Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol.1990; 25(6): 613–622.
26.
PelcI., VerbanckP., Le BonO.Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry.1997; 171: 73–77.
27.
LhuintreJ-P, DaoustM., MooreN.D.Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet.1985; 1(8436): 1014–1016.
28.
ChickJ., HowlettH., MorganM.Y.United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol.2000; 35(2): 176–187.
29.
NamkoongK., LeeB.O., LeeP.G.Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcoholism.2003; 38(2): 135–141.
30.
RubioG., Jimenez-ArrieroM.A., PonceG.Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcoholism.2001; 36(5): 419–425.
31.
KranzlerH.R., Van KirkJ.Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res.2001; 25(9): 1335–1341.
32.
KieferF., JahnH., TarnaskeT.Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry.2003; 60(1): 92–99.
33.
BessonJ., AebyF., KasasA., LehertP.Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol.1998; 22(3): 573–579.
34.
Morgan MY, Landron F, Lehert P, New European Alcoholism Treatment Study Group.Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support. Alcohol Clin Exp Res.2004; 28(1): 64–77.
35.
HammarbergA., WennbergP., BeckO.A comparison of two intensities of psychosocial intervention for alcohol dependent patients treated with acamprosate. Alcohol Alcohol.2004; 39(3): 251–255.
36.
PelcI., AnsomsC., LehertP.The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction. Alcohol Clin Exp Res.2002; 26(10): 1529–1538.
37.
De WildtW.A., SchippersG.M., Van Den BrinkW.Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems?Alcohol Alcohol.2002; 37(4): 375–382.
38.
PalmerA.J., NeeserK., WeissC.The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol.2000; 35(5): 478–492.
39.
SchädlichP.K., BrechtJ.G.The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study. Pharmacoeconomics.1998; 13(6): 719–730.
40.
FosterR.H., McClellanK.J.Acamprosate. Pharmacoeconomic implications of therapy. Pharmacoeconomics.1999; 16(6): 743–755.
41.
MasonB.J.Methodology of the U.S. multicenter study of acamprosate in alcohol dependence [abstract]. Eur Psychiatry.1998; 13(Suppl 4): 154s.
42.
MasonB.J., GoodmanA.M.Acamprosate treatment of alcohol dependence: results of the U.S. multicenter study [abstract]. Biol Psychiatry.2001; 49: 14S.
43.
MasonB.J.Results of the multicenter study of acamprosate in the treatment of alcoholism [abstract]. Biol Psychiatry.2001; 49: 77S.
44.
TempestaE., JaniriL., BignaminiA.Acamprosate in alcohol dependence: a placebo-controlled study in a comprehensive post-detoxification program [abstract]. Eur Psychiatry.1998; 13(Suppl 4): 234S.
45.
COMBINE Study Research Group.Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol Clin Exp Res.2003; 27(7): 1107–1122.
46.
COMBINE Study Research Group.Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): a pilot feasibility study. Alcohol Clin Exp Res.2003; 27(7): 1123–1131.
47.
MannK., LehertP., MorganM.Y.The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res.2004; 28(1): 51–63.
48.
ChickJ., LehertP., LandronF.Does acamprosate improve reduction of drinking as well as aiding abstinence?J Psychopharmacol.2003; 17(4): 397–402.
49.
SchneiderU., WohlfahrtK., Schulze-BonhageA.Lack of psychomimetic or impairing effects on psychomotor performance of acamprosate. Pharmacopsychiatry.1998; 31(3): 110–113.
50.
SchneiderU., WohlfarthK., Schulze-BonhageA.Effects of acamprosate on memory in healthy young subjects. J Stud Alcohol.1999; 60(2): 172–175.
51.
SoykaM., AichmullerC., PreussU.Effects of acamprosate on psychomotor performance and driving ability in abstinent alcoholics. Pharmacopsychiatry.1998; 31(6): 232–235.
52.
MasonB.J., GoodmanA.M., DixonR.M.A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology.2002; 27(4): 596–606.
